

# ALZHEIMER'S DISEASE

## MT-PROMOTION THERAPY

*Albert Mensah, M.D.*

# Sydney Physician-Training

May 2 to May 11, 2010



## Objectives

1. Transfer advanced biochemical therapy technology to Australia physicians.
2. Enable Australia families to access this effective treatment modality.

# 2010 Sydney Outreach Team



- Bio-Balance Health Association
  - Bruce Jeanes
  - Judy Nicol
  - John Skelton
- Marnie Redstone Lo (Sydney Coordinator)
- Physician-Training Faculty
  - Bill Walsh, PhD
  - Jim Neubrandner, MD
  - Mary Megson, MD
  - Albert Mensah, MD

# Alzheimer's Disease



- Severe oxidative stress
- Amyloid plaque and neurofibrillary tangles
- Metal-metabolism disorder
- Elevated toxic metals
- Low levels of metallothionein in ALZ brains.

# Low MT Levels Can Produce Amyloid



- MT proteins protect the brain from metal free radicals,
- Metal free radicals (iron, copper, zinc) enhance formation of beta amyloid plaque in the brain,
- AD autopsy studies show MT levels less than 1/3 of normal concentrations.

# Metallothionein-Promotion Therapy for Alzheimer's Disease



- Formulation of 22 nutrients that promote synthesis and functioning of MT.
- Zinc loading followed by MT-Promotion.

**Note: *MT-Promotion is aimed at overcoming brain oxidative stress & inflammation, and repair of the blood/brain barrier.***

# Early Clinical Results



- Most patients reported partial improvement of memory followed by stabilization of condition.
- Several patients have lost the diagnosis of AD due to lack of progression of the disease after several years.
- Caretaker needed for effective compliance.
- We consider this therapy highly promising, but unproven.

# Albert Mensah, M.D.



- World's most experienced physician for treatment of Alzheimer's and Parkinson's patients using MT-Promotion Therapy.